A Star in deal with AUM Biosciences and One Biomed
- by Team ABLE - 05 Dec, 2018
Singapore headquartered AUM Biosciences (AUM) has licensed its first novel, highly selective anti-cancer drug, ETC-206, from A*STAR's Experimental Therapeutics Centre (ETC). The Agency for Science, Technology and Research (A*STAR) is Singapore's public sector agency that spearheads economic oriented research to advance scientific discovery and develop innovative technology.
AUM has licensed the global rights to develop, commercialize and manufacture ETC-206 in all indications. ETC-206 was discovered and developed through a collaboration between A*STAR 's Experimental Therapeutics Centre (ETC) and Duke NUS Medical School (a partnership between Duke University School of Medicine and the National University of Singapore). It advanced into first-in-man trials in December 2016. Initial clinical studies suggest that ETC-206 is very well tolerated and could be used as a therapy across a range of liquid and solid tumor types.
The drug promises a more targeted approach by inhibiting the Mnk enzyme in cancer cells, which is a key player in promoting cancer growth when activated. This could lower mortality rates for cancer and improve quality of life for cancer patients compared to traditional chemotherapy, which kills cells in a less specific fashion and affects more than just the cancer cells.
ETC-206 is the first in AUM's pipeline of novel targeted therapies with the potential to be developed both independently and in combination with other therapies. The drug's ability to isolate and target only cancerous cells promises a breakthrough opportunity globally.
A*Star-One Biomed joint lab
A*STAR's Institute of Microelectronics (IME) and One BioMed, an A*STAR spin-off, launched a S$9 million joint lab on 29th November. The aim is to launch within the next five years, a point-of-care diagnostic kit that can test for up to 20 types of infectious diseases simultaneously in just 20 minutes.
In two separate dealings, AUM Biosciences has licensed its first novel, highly selective anti-cancer drug from A*STAR's Experimental Therapeutics Centre (ETC) and A*STAR's Institute of Microelectronics (IME) and One BioMed have launched a S$9 million joint lab.